What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2026-03-18 compared with 2025-04-15 · 19 added, 32 removed, 27 unchanged (65% of the section changed)

ITEM 5 – MARKET FOR REGISTRANT’S

COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5 - MARKET FOR

REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our Common Stock is currently traded on the Nasdaq

1 unchanged sentence

that, on the NYSE Amex.

As of April 11, 2025, there were 3,050,770 shares

of our Common Stock issued and outstanding, and the Company had approximately 47 record holders of Common Stock.

The number of holders

of record does not include the number of persons whose stock is in nominee or “street name” accounts through brokers.

As of March 16, 2026, there were 5,240,544 shares of our Common Stock

issued and outstanding, and the Company had approximately 34 record holders of Common Stock.

The number of holders of record does not

include the number of persons whose stock is in nominee or “street name” accounts through brokers.

Dividend Policy

2 unchanged sentences

The payment of dividends is at the discretion of the Board and is contingent on our revenues and earnings, capital

requirements, financial condition and the ability of our operating subsidiaries to obtain governmental approval to send funds out of the

requirements, financial condition and the ability of our operating subsidiaries to obtain governmental approval to send funds out of

We currently intend to retain all earnings, if any, for use in business operations.

Accordingly, we do not anticipate declaring any

dividends in the near future.

Accordingly, we do not anticipate declaring

any dividends in the near future.

The PRC’s national currency, the RMB or

6 unchanged sentences

The Company did not make any sales of unregistered

securities during the fiscal year ended December 31, 2024 that were not previously disclosed in a quarterly report on Form 10-Q or a current

report on Form 8-K.

securities during the fiscal year ended December 31, 2025 that were not previously disclosed in a quarterly report on Form 10-Q or a

current report on Form 8-K.

Securities Authorized for Issuance Under Equity Compensation Plans

2 unchanged sentences

not previously approved by stockholders.

The number of shares are pre-2025 Reverse Stock Split.

Equity Compensation Plan Information

3 unchanged sentences

Equity compensation plans not approved by stockholders

Consists of Company’s 2024 Omnibus Equity

Plan, which was approved by the Company’s shareholders at its annual meeting of stockholders on December 5, 2024, which was approved

and adopted by the Board on October 12, 2024, to provide equity awards to employees, directors and consultants of the Company (the “2024

There are 5,000,000 shares of commons stock available for awards under 2024 Plan.

On March 10, 2025, the Compensation Committee

of the Board granted stock awards of 5,000,000 shares of common stock of the Company, pursuant to the Company’s 2024 Omnibus Equity

Plan, to sixteen officers and employees of the Company and its subsidiaries, including:

300,000 shares to Hu Li, Chief Executive Officer

of the Company.

On December 23, 2023, the Compensation Committee

of the Board of Directors (the “Board”) of the Company granted stock awards of 2,890,000 shares of common stock of the Company,

pursuant to the Company’s 2023 Omnibus Equity Plan, to sixteen officers and employees of the Company and its subsidiaries (the

“Grantees”), including:

200,000 shares to Shanchun Huang, then Chief Executive Officer and President of the Company, 40,000

shares to Peng Lei, Chief Operating Officer of the Company, and 30,000 shares to Hu Li, then Corporate Secretary of the Company (collectively,

the “Grants”).

The Grants vested immediately on the Grant Date and each of the Grantees also entered into an Unrestricted

Stock Award Agreement with the Company on December 23, 2023.

On October 4, 2024, the Company granted the remaining 2,110,000 share

under 2023 Omnibus Equity Plan to 4 employees of the Company and its subsidiaries.

At the Company’s 2025 Annual Meeting of Stockholders, stockholders approved an equity incentive plan authorizing the issuance of

up to 5,000,000 shares of the Company’s common stock.

The amounts presented in the table above reflect the number of shares authorized

under the plan as of December 31, 2025.

On January 20, 2026, the Company effected a 1-for-4 reverse stock split, and the number of shares

authorized under the plan was proportionately adjusted to approximately 1,250,000 shares.

As of December 31, 2025, no awards had been granted under the plan, and no shares were subject to outstanding options, warrants, or other

The Company has not filed a registration statement on Form S-8 with respect to the shares reserved under the plan.

ITEM 6 - [RESERVED]

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity